Cancer Stem Cells Market Report 2025

The cancer stem cells market size has grown rapidly in recent years. It will grow from $2.93 billion in 2024 to $3.24 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. Growth during the historic period can be attributed to increased funding for research on stemness pathways, the expansion of flow cytometry and cell sorting capabilities in academic institutions, incorporation of cancer stem cell endpoints in preclinical oncology studies, advancements in niche and microenvironment research, and a surge in publications on cancer stem cell biology and therapy resistance mechanisms.

The cancer stem cells market size is expected to see rapid growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The anticipated growth in the forecast period can be linked to the rising adoption of comprehensive genomic profiling and whole transcriptome analysis in hospitals, increasing demand for minimal residual disease monitoring in both solid and hematologic cancers, wider use of circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) testing, scaling up of single-cell sequencing and proteomics in clinical research networks, and growing prevalence of therapy-resistant and relapsed cancer cases. Key trends expected in the forecast period include the integration of single-cell multi-omics combining genomics, transcriptomics, proteomics, and epigenomics; AI- and ML-assisted detection of rare tumor-initiating cells; microfluidics-based gentle cell sorting and closed-system sample handling; development of organoid and tumoroid co-culture models incorporating immune and stromal components; and spatial transcriptomics and spatial proteomics for mapping stemness niches.

The rising demand for personalized medicine is expected to drive growth in the cancer stem cells market in the coming years. Personalized medicine refers to treatment approaches designed according to the genetic profile, tumor biology, and individual response patterns of each patient, aiming to increase treatment effectiveness while minimizing side effects. Demand for personalized medicine is rising due to the wider availability and affordability of genomic sequencing technologies, which are increasingly used in oncology research and clinical practice. In cancer treatment, personalized medicine targets cancer stem cells (CSCs) by tailoring therapies to the unique molecular and genetic characteristics of a patient’s tumor. Tumors are analyzed for mutations, signaling pathways, and surface markers specific to their CSC population, enabling clinicians to select therapies that inhibit critical pathways. For example, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Consequently, the growing focus on real-time risk assessment and tailored cancer therapies is driving the expansion of the cancer stem cells market.

Companies in the cancer stem cells market are also advancing technology to improve research and diagnostics. Pre-analytical immunomagnetic sorting systems, for example, use magnetic particles coated with antibodies to isolate specific CSC populations from complex biological samples, enhancing sensitivity and reproducibility in downstream assays. In March 2024, STEMCELL Technologies, a Canada-based biotechnology company, launched the EasySep Human Bone Marrow CD138 Positive Selection Kit. This kit, the first hematopoietic cell enrichment product to receive FDA de novo classification as a Class II in vitro diagnostic device, enriches CD138+ plasma cells from bone marrow samples to improve detection of multiple myeloma-related abnormalities. By providing high-purity cell populations, the product strengthens the pre-analytical stage of cancer diagnostics, supporting more reliable downstream testing and improved patient outcomes.

In March 2023, Sona Nanotech Inc., a Canada-based nanotechnology and life sciences company, acquired Siva Therapeutics Inc. for $2 million. The acquisition aims to accelerate the development of Targeted Hyperthermia Therapy (THT) for colorectal cancer by combining Siva’s photothermal treatment platform with Sona Nanotech’s proprietary biocompatible gold nanorods. This integration enables minimally invasive procedures that stimulate immune response, shrink tumors, and enhance drug delivery across multiple cancer types. Siva Therapeutics Inc., based in the US, specializes in photothermal cancer therapies using gold nanorod-based heat delivery systems.

Major players in the cancer stem cells market are MacroGenics Inc., Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Lonza Group AG, A. Menarini Industrie Farmaceutiche Riunite S.r.l., Bio-Techne Corporation, Zymeworks Inc., Kura Oncology Inc., GeneTex Inc., YZY Biopharma Co. Ltd., Abnova (Taiwan) Corporation, BioView Ltd., ScienCell Research Laboratories Inc., Boster Biological Technology Co. Ltd., BioFluidica Inc., AAT Bioquest Inc., Celprogen Inc., Actinium Pharmaceuticals Inc.

North America was the largest region in the cancer stem cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer stem cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer stem cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Cancer stem cells (CSCs) are a small subset of cells within a tumor that exhibit stem cell-like properties, including the ability to self-renew and differentiate into multiple cell types that form the bulk of the tumor. These cells are thought to play a key role in tumor initiation, progression, metastasis, and recurrence, primarily due to their resistance to conventional treatments such as chemotherapy and radiation.

The main categories of cancer stem cells include solid tumor stem cells, hematopoietic stem cells, breast cancer stem cells, colorectal cancer stem cells, brain cancer stem cells, and leukemia stem cells. In many solid tumors, a small population of CSCs drives tumor growth, demonstrates self-renewal, and has the capability to regenerate the tumor’s cellular heterogeneity, thereby contributing to therapy resistance and recurrence. The cancer types associated with CSCs include breast, blood, lung, brain, colorectal, pancreatic, bladder, liver, and others, where CSCs play a role in the mechanism of stem cell-based cancer therapy. Research approaches encompass basic research, clinical research, preclinical studies, and translational research, conducted by pharmaceutical and biotechnology companies, research and academic institutions, hospitals and laboratories, and contract research organizations (CROs).

The cancer stem cells market research report is one of a series of new reports that provides cancer stem cells market statistics, including cancer stem cells industry global market size, regional shares, competitors with a cancer stem cells market share, detailed cancer stem cells market segments, market trends and opportunities, and any further data you may need to thrive in the cancer stem cells industry. This cancer stem cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer stem cells market includes of revenues earned by entities by providing services such as biomarker identification, preclinical testing, clinical trial support, cell characterization and therapeutic development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.